Navigation Links
DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
Date:7/29/2010

CUPERTINO, Calif., July 29 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, August 4, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation.  Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- The Board of Directors of NeuroVive Pharmaceutical AB ... is to take place on Thursday, April 27, 2017, at 4 ... . ... see the attached notification, which is being announced within short in ... AB (Publ) The Board Of Directors About NeuroViveNeuroVive Pharmaceutical ...
(Date:3/22/2017)... 22, 2017  "Global Biosimilar Insulin Market ... gives comprehensive insight on clinical and non-clinical ... insulin market. This report analyzes various aspects ... of insulin in diabetes, engineering of synthetic ... with market overview, biosimilar insulin clinical pipeline ...
(Date:3/22/2017)... 2017 New Jersey,s ... harm and saved $641 million in healthcare costs between ... national quality improvement program. The results ... Jersey, part of a national initiative from the U.S. ... New Jersey Hospital Association and its affiliate, the Health ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 23, 2017 , ... Death anxiety is unconscious and ... author Joy Nugent was inspired to write the book titled “ As Good as ... desire to make sense of what she was experiencing at the bedside of patients ...
(Date:3/22/2017)... ... March 22, 2017 , ... Sam & Associates Insurance ... planning, and related services to residents of the region, is embarking on a ... species and wild lands. , Endangered Species International is committed to ending the ...
(Date:3/22/2017)... ... 2017 , ... Old School Labs™, makers of the best-selling Vintage line of ... Ambassador. Theophane, who trained with Floyd Mayweather, made his professional debut in London in ... an impressive number of wins in contests in Britain, Germany and the U.S. ...
(Date:3/22/2017)... ... March 22, 2017 , ... In recognition of ... media enterprise focused on cancer patients, cancer centers and advocacy groups, and MJH ... educational video series, “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 individuals worldwide. ... the X chromosome, and almost exclusively strikes females. Following a normal infancy, ...
Breaking Medicine News(10 mins):